Overview

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Status:
Recruiting

Trial end date:
2029-09-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.

Phase:

Phase 2

Details

Lead Sponsor:

ModernaTX, Inc.

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab